SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
MINNEAPOLIS, Nov. 22, 2016 -- Lockridge Grindal Nauen P.L.L.P. announces that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NYSE:ALXN) securities between February 10, 2014 through November 9, 2016 (the “Class Period”).
If you are a member of the proposed Class, you may move the Court to serve as a lead plaintiff for the Class on or before January 17, 2017. You do not need to be a lead plaintiff in order to share in any recovery that may be obtained.
The Complaint alleges Alexion made false and/or misleading statements and/or failed to disclose: 1) that the Company employed improper sales practices with respect to its product Soliris; 2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and 3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times. On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. Following the cancellation, analysts noticed that the Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On this news, Alexion’s share price fell $8.95, or 6.94%, to close at $120.05 on November 7, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this information was disclosed, shares of Alexion declined in value, causing investors harm. On this news, Alexion’s share price fell $0.28, or 0.22%, to close at $126.88 on November 10, 2016. As the market continued to digest the significance of Alexion’s announced investigation, Alexion’s share price fell an additional $13.26, or 10.45%, to close at $113.62 on November 11, 2016.
If you purchased Alexion Pharmaceuticals, Inc. stock during the Class Period, or have any questions concerning this notice or your rights with respect to this matter, please contact:
Gregg M. Fishbein, Esq. ([email protected])
Lockridge Grindal Nauen P.L.L.P.
100 Washington Avenue South, Suite 2200
Minneapolis, MN 55401
(612) 339-6900
